Petros Pharmaceuticals, INC Form 4 insider transactions

Director Wayne Remell Walker acquired 375,000 restricted shares of Petros Pharmaceuticals, Inc. common stock.

President and Chief Commercial Officer Fady Boctor acquired 375,000 restricted shares of Petros Pharmaceuticals common stock.

Director Bruce Bernstein acquired 1,875,000 restricted shares of Petros Pharmaceuticals, Inc. common stock.

Petros Pharmaceuticals director Joshua Silverman was granted 4,375,000 restricted shares of common stock.

Petros Pharmaceuticals' President & Chief Commercial Officer, Fady Boctor, acquired 500,000 Restricted Stock Units.

Petros Pharmaceuticals Director Joshua Silverman acquired 4,375,000 Restricted Stock Units, with a vesting schedule tied to continued service, adjusted for a recent reverse stock split.

Petros Pharmaceuticals Director Wayne Remell Walker was granted 500,000 Restricted Stock Units, with vesting contingent on continued service.

Petros Pharmaceuticals Director Bruce Bernstein acquired 1,875,000 Restricted Stock Units, with vesting tied to continued service, adjusted for a recent reverse stock split.

Wayne Remell Walker, a director at Petros Pharmaceuticals, acquired 150,000 shares of common stock through a grant of restricted shares.

Mitchell Arnold, Vice President of Finance & Chief Accounting Officer at Petros Pharmaceuticals, was granted 150,000 restricted shares of common stock on February 19, 2025.

Director Joshua Silverman acquired 1,000,000 restricted shares of Petros Pharmaceuticals common stock on February 19, 2025, at no cost.

Fady Boctor, a principal officer at Petros Pharmaceuticals, was granted 450,000 shares of restricted common stock on February 19, 2025, under the company's incentive plan.

Director Bruce Bernstein acquired 300,000 shares of Petros Pharmaceuticals restricted stock on February 19, 2025, under the company's incentive plan.